Physician profile
Paul Gardial
NPI 1639170194
$7,738.17
in general payments reported to CMS, 2019-2025
46 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $1,286 · 2021: $1,463 · 2022: $1,127 · 2023: $1,068 · 2024: $935 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,037 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,037.24 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,181.72 | 2019-2025 | |
| Pfizer INC. | $867.70 | 2019-2025 | |
| Lilly USA, LLC | $728.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $546.02 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $491.69 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $446.66 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $388.97 | 2021-2025 | Freestyle Libre 3, Cardiomems |
| Otsuka America Pharmaceutical, INC. | $336.37 | 2019-2025 | Rexulti |
| Amarin Pharma, INC. | $303.07 | 2019-2022 | |
| Amgen INC. | $238.30 | 2019-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $196.62 | 2019-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $177.94 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $149.39 | 2019-2023 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $146.16 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $142.73 | 2024-2025 | Voquezna |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Gardial listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.